menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Tirzepatides & Therapeutic Inertia: Highlights from ADA

ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    From newly approved treatments to emerging clinical trial data, Dr. Carol Wysham shares some of the highlights from the American Diabetes Association’s 82nd Scientific Sessions, exploring developments in GLP-1 receptor agonists, barriers to patient use, and more.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    From newly approved treatments to emerging clinical trial data, Dr. Carol Wysham shares some of the highlights from the American Diabetes Association’s 82nd Scientific Sessions, exploring developments in GLP-1 receptor agonists, barriers to patient use, and more.

Facebook Comments

Schedule26 Jun 2022
Webpack App